Signals Inbox·July 19, 2026·InsurTech

Is Alan really worth $6.3B today?

Alan’s $6.3 billion valuation is aggressive on today’s economics, but its exceptional growth, French profitability and improving efficiency give the company a credible path to grow into it.

Q1What actually happened in Alan’s latest funding round?

Alan’s new $6.3 billion valuation comes from a real transaction, although the company did not receive the full amount announced. Prosus led a €480 million financing that valued Alan at €5.5 billion, or approximately $6.3 billion. Prosus contributed €400 million, while Teachers’ Venture Growth, Index Ventures and the new investor Dara Holdings completed the round.

Part of the transaction involved newly issued shares, while another part allowed employees and existing investors to sell their holdings. Alan and Prosus did not disclose the split. We therefore know how much money changed hands, but not exactly how much fresh capital entered Alan’s bank account.

The valuation moved unusually quickly. Alan had raised €100 million at a €5 billion valuation only three months earlier. Investors increased the company’s price by another €500 million before Alan had published a full new year of financial results.

Prosus also had strategic reasons to pay a high price. It wants Alan to use its AI infrastructure, expand through its international network and eventually reach customers across the wider Prosus portfolio. The deal reflects more than Alan’s standalone financial performance.

Still, €5.5 billion is the price investors accepted. Alan now has to prove that the underlying business can catch up with it.

Q2How did Alan become a $6.3B company so quickly?

Alan reached a $6.3 billion valuation roughly ten years after its creation, and most of that increase happened during the last four years. The company was worth €2.7 billion in 2022, €4 billion in 2024, €5 billion in early 2026 and €5.5 billion three months later.

The valuation has slightly more than doubled since 2022. Over the same period, Alan’s annualized premium volume rose from roughly €200 million to more than €800 million. The business grew considerably faster than the valuation.

That comparison makes today’s price look less irrational than the raw number suggests. Investors paid around 13.5 times annualized premiums in 2022. The latest deal values Alan at approximately 6.8 times premiums.

Alan has become more valuable in absolute terms while becoming cheaper relative to its insurance volume. The difficult question is whether premiums are the right metric to use in the first place.

Alan’s valuation and operating scale by funding round

Q3Is Alan’s €804M ARR as good as it looks?

Alan’s €804 million ARR overstates the amount of revenue that the company can actually keep. Alan uses ARR to describe the annualized insurance premiums attached to signed contracts. It does not represent high-margin software subscriptions.

Alan’s 2025 regulatory report makes the difference visible. The company entered 2026 with €785 million in signed annual premiums, but it recognized only €427 million in earned premiums during 2025. Some contracts had been signed but had not yet produced a full year of accounting revenue.

Claims then absorb most of those earned premiums. When a member visits a doctor, buys medicine or receives treatment, Alan uses premium income to reimburse part of the cost.

Alan’s management has previously described its core fee as roughly 12% to 14% of premiums. Applying that range to €804 million gives approximately €96 million to €113 million in revenue that resembles a software or service fee more closely.

Alan also earns commissions, financial income and revenue from additional products, so this remains an approximation. Yet it provides a much better picture of the economics than calling the full €804 million technology revenue.

Q4Is Alan’s 6.8x premium multiple too high?

Alan’s 6.8x multiple looks manageable until we adjust for the premiums paid back through healthcare claims. Using Alan’s estimated retained fee instead, the company trades at roughly 49 to 57 times its current fee-like revenue.

That is expensive even for a fast-growing technology company. Investors are already paying for several years of continued growth and margin improvement.

The calculation also looks demanding at the member level. Alan is valued at roughly €5,000 for every insured member. Each member currently represents about €730 in annual premiums, of which Alan may retain only €88 to €102 before operating expenses.

Investors are paying close to 50 years of today’s annual fee per member. The investment can still work because Alan should add members, sell more services and lower its operating cost per customer. Without those improvements, the current economics cannot support the price.

The headline multiple is too flattering. Alan deserves a higher multiple than a traditional insurer, but treating all premiums like SaaS revenue gives the company far too much credit.

Q5Is Alan still growing fast enough today?

Alan is currently growing fast enough to justify a large premium over traditional insurers. Signed annual premiums increased by 53% during 2025, while recognized premiums rose by 55%.

That growth is exceptional at Alan’s size. France’s complementary health insurance market grew by 8.2% in 2024, according to the latest DREES industry report. Alan expanded more than six times faster than its main domestic market.

Healthcare inflation alone cannot explain that gap. Alan has been taking contracts and members from established insurers, mutual organizations and employee-benefit providers.

The company also became more productive. Alan reported 60% more new business during the first quarter than one year earlier while keeping sales and marketing investment broadly stable. In 2024, revenue had already risen by 48% while total headcount increased by only 8%.

Those figures support a genuine technology premium. They do not make Alan a software company, since claims still consume most premium income. But Alan is clearly operating more efficiently than a normal insurer growing at single-digit rates.

Q6Is Alan growing because members pay more or because it keeps adding members?

Alan’s latest growth came almost entirely from adding members rather than charging each member substantially more. Signed annual premiums rose by 53% during 2025, while signed membership increased by 52%.

Annual premiums per signed member moved from approximately €735 to €741. That is an increase of less than 1%, even before adjusting for healthcare inflation.

That is reassuring in one sense. Alan did not manufacture its growth through aggressive price increases. It won more insured lives while keeping average premiums broadly stable.

It also exposes a weakness. Alan currently has little visible revenue expansion inside its existing member base. Growth depends mainly on winning new employers, institutions and public tenders.

One large contract had a meaningful effect. Alan onboarded more than 130,000 Finance Ministry agents during 2025. The company added roughly 362,000 signed members overall, making that deployment equivalent to about 36% of its net additions.

As we saw earlier, Alan’s 53% growth rate is real. It is also heavily driven by customer acquisition and a few major contracts rather than stronger monetization.

Q7Is Alan profitable yet?

Alan is profitable in France, but the full group still loses money. The French operation reached positive EBITDA during 2025, giving Alan its first proof that the business can become profitable in a mature market.

At group level, the net loss fell from €34 million to €26 million. That improvement happened while the business expanded by more than half, so losses are becoming much smaller relative to Alan’s scale.

Alan’s regulated insurance entity separately reduced its net loss from €17.7 million to €11.9 million. It also held more than €325 million in cash before the latest financing.

The financial direction is healthy. Alan is not doubling its losses to maintain growth, and the core French business no longer needs permanent subsidies from investors.

The current valuation still cannot be explained by profits. Even €26 million in annual earnings would leave Alan trading above 200 times profit. Investors need France’s profitability to spread across Belgium, Spain, Canada and the group’s newer products.

Alan currently expects group profitability in 2027. That target looks credible. The valuation assumes the company will move far beyond simple break-even.

Q8How does Alan’s valuation compare with Oscar, Alignment and Lemonade?

Alan trades at a much higher revenue multiple than public health insurers, even when those insurers are growing quickly. Oscar Health is valued at less than one times annual revenue. Alignment Healthcare trades at approximately one times revenue.

Alignment offers the sharpest comparison. Its revenue grew by 46% during 2025, only seven percentage points slower than Alan’s signed premium growth. Alignment also produced positive adjusted EBITDA and free cash flow, yet its revenue multiple remains around one-sixth of Alan’s.

Lemonade receives a valuation closer to Alan’s because investors also see it as an insurance technology platform. Its market value represents roughly seven times annual revenue. Lemonade, however, continues to report substantial net losses.

Alan deserves some premium because it is smaller, expanding more quickly and still has new markets to enter. A sixfold gap with Alignment remains difficult to defend using growth alone.

Public markets currently treat health insurers as low-margin financial businesses. Alan’s investors are betting that it will eventually resemble a healthcare software platform that happens to include insurance.

Alan’s valuation compared with selected public insurers

Q9Do recent healthtech deals make Alan look cheap?

Recent healthtech deals prove that investors will pay Alan-like valuations, but they do not make Alan look cheap. Several companies have reached even larger values with less operating scale.

Devoted Health reportedly reached a valuation of around $13 billion after raising another $366 million across late 2025 and early 2026. The US Medicare insurer began 2026 with more than 466,000 members, less than half Alan’s membership.

Neko Health raised $700 million at a valuation approaching $7 billion. At the time, the company had scanned around 100,000 people and operated only eight clinics. Neko owns specialized hardware and has strong consumer demand, although its commercial footprint remains much smaller than Alan’s.

The most useful comparison is Wefox. The European insurtech reached a $4.5 billion valuation in 2022 before underwriting losses and financing pressure forced a severe restructuring. Two years later, some of its main assets were being discussed at a value of roughly €550 million.

Alan is in a stronger position than Wefox was. France is profitable, group losses are narrowing, and the company has enough capital to avoid an urgent financing problem.

Even so, Wefox shows how quickly investors can abandon an insurtech valuation when premium growth fails to produce attractive margins. Private-market precedent makes Alan’s valuation possible, not comfortable.

Q10Is France big enough to support a $6.3B Alan?

France is easily big enough to support Alan’s valuation, although Alan still controls only a small share of the market. French complementary health insurers collected approximately €46.5 billion in premiums during 2024.

Alan is estimated to generate around 80% of its business in France. Applying that proportion to its year-end premium volume suggests roughly €628 million in signed French premiums.

That would place Alan at approximately 1.35% of the national market. Alan reports signed annual premiums while the French market figure covers premiums already recognized, but the order of magnitude is clear.

At a 5% domestic market share, Alan would represent around €2.3 billion in annual premiums before adding Belgium, Spain, Canada or non-insurance products. The market can accommodate several years of continued growth.

Competition will be intense. The five largest French insurance groups already collect almost half of all complementary health premiums, while the 20 largest organizations control 58%.

Alan does not need a larger market. It needs to keep taking customers from organizations with stronger broker networks, deeper balance sheets and much longer employer relationships.

Q11Can Alan keep growing this fast now?

Alan will probably grow more slowly from now on, and its own targets already point toward that slowdown. The company entered 2026 with €785 million in signed annual premiums and aims to exceed €1 billion by the end of the year.

Reaching exactly €1 billion would mean growth of roughly 27%. That would still be excellent for an insurer, but close to half the previous year’s rate.

Alan finished the first quarter at €804 million, only 2.4% above its year-end level. Insurance contracts arrive unevenly, particularly when large employers renew coverage at fixed points in the year, so one quarter cannot be extrapolated mechanically.

Commercial activity looks stronger than that small increase suggests. Alan reported 60% more new business with broadly similar sales and marketing spending.

As pointed out above, the previous 53% growth rate relied partly on major public contracts. Alan can justify its valuation while slowing toward 30%. A decline toward 15% or 20% would create a much larger problem, especially if international markets remain unprofitable.

Q12Can Alan really win outside France?

Alan has proved that it can attract customers outside France, but it has not yet built another profitable national business. Belgium currently provides the strongest evidence.

Belgian signed membership increased by 134% during 2025 and passed 166,000. The partnership with Belfius gives Alan access to companies, public institutions and smaller employers without requiring the company to build every sales channel itself.

Spain grew by 42%, although it remains much smaller with approximately 27,000 signed members. That represents less than 3% of Alan’s total membership.

Canada is earlier still. Alan has obtained several provincial approvals and started commercial operations, but it has not disclosed enough members or premium volume to judge whether the launch is working.

Alan’s expansion model also changes from country to country. Belgium depends heavily on a major distribution partner. Spain relies more directly on Alan’s own sales. Canada brings different regulations, benefit structures and medical costs.

Belgium may become a genuine second engine. Spain and Canada remain promising experiments. The current valuation gives Alan credit for all three before the company has shown that they can match France’s economics.

Q13Are Alan’s government contracts a real moat?

Alan’s government contracts create valuable switching costs, although they do not prevent competitors from winning the next tender. The company now covers employees from the French Finance Ministry, the Prime Minister’s services, the Ecology Ministry, the National Assembly and the civil aviation authority.

These deployments require more than selling an insurance policy. Alan has to connect administrative systems, migrate member information, explain new coverage rules, manage claims and coordinate with public-sector payroll teams.

Once more than 100,000 people have completed that process, changing insurer becomes disruptive. The contract also gives Alan a powerful reference when approaching other large institutions.

The Finance Ministry deployment shows the other side of the model. Its 130,000 agents represented a substantial share of Alan’s member growth during 2025. Losing a large renewal, or accepting weaker pricing to preserve it, could materially affect future results.

Government contracts give Alan credibility, volume and a higher chance of renewal. They are a distribution advantage, not permanent protection from competition.

Q14What can Alan do that AXA or Allianz cannot easily copy?

AXA, Allianz and large French mutual insurers can copy most of Alan’s visible features. They can build better applications, add AI assistants, reimburse claims faster and include telemedicine in employer plans.

Alan’s advantage comes from operating all those services through one modern system. It built its technology, insurance operations, claims handling and member interface together, without decades of legacy software or separate business units.

The company has also learned how to onboard unusually large organizations. It now works with more than 35,000 companies and public bodies, including deployments involving over 100,000 members.

Alan combines insurance, prevention, mental-health support, occupational health and consumer health services inside one relationship. That gives the company more opportunities to interact with members than a traditional insurer that appears mainly when a claim needs reimbursement.

Its partnership with Belfius adds another advantage. Alan turned an established bank and insurer into an investor and distribution channel instead of trying to replace it directly.

None of this creates an impossible barrier. Incumbents have more capital, larger broker networks and long-standing employer contracts. Alan’s edge depends on continuing to move faster and operate more efficiently. Slow down, and they can catch it.

Q15Is Alan’s AI actually saving money today?

Alan’s AI is already reducing manual work, although we cannot yet isolate how much profit it creates. The clearest result comes from claims processing.

Alan automatically processed 72% of reimbursement documents during 2025, up from 67% one year earlier. Every additional automated claim reduces the amount of repetitive work handled by employees.

Sales productivity improved at the same time. Alan generated 60% more new business during the first quarter without increasing commercial investment at a similar rate.

Mo, Alan’s AI health assistant, is now available to more than 500,000 members in France. The company reports four times more engagement than with its previous human-led Clinic service. It also says 81% of users choose Mo when given the option, including many who initially arrived looking for a doctor.

Those products are being used, not merely displayed in investor presentations. They help Alan answer questions, process claims and support customer acquisition.

The direct financial contribution remains unclear. Alan has not disclosed how much of its margin improvement came from AI rather than pricing, reinsurance, contract mix or ordinary scale.

AI already makes Alan’s operations better. The missing proof is whether it can materially improve the percentage of premiums Alan keeps.

Q16How much revenue would Alan need to justify a $6.3B valuation?

Alan needs between roughly €183 million and €550 million in retained annual revenue to justify its valuation under common growth-company multiples. The exact target depends on how highly investors value the business once growth begins to slow.

As discussed earlier, applying Alan’s 12% to 14% fee range to current premiums gives roughly €105 million in fee-like annual revenue at the midpoint.

A highly valued growth platform trading at 30 times revenue would need approximately €183 million. At 20 times revenue, Alan would need €275 million. A 10 times multiple would require €550 million.

If retained revenue continued growing at 53% every year, Alan could reach the 20 times threshold in slightly more than two years. Its own annual target suggests growth will probably be slower, so a realistic path could take three to four years.

The valuation is pricing Alan several years ahead. That becomes acceptable when growth remains above 30% and group margins improve at the same time.

Retained revenue required to support Alan’s current valuation

Q17What would make Alan worth more than $6.3B?

Alan could become worth considerably more than $6.3 billion by turning its French insurance success into a broader European healthcare platform. Premium growth alone will not be enough.

France must produce expanding profits rather than simply remaining slightly above break-even. Belgium needs to become a large and eventually profitable second market. Spain and Canada need to show that Alan can expand without relying on one local partnership or a single regulatory model.

Alan also needs more revenue that does not flow directly back into medical claims. Mo, occupational health, prevention services, commissions and consumer health products could gradually raise the amount of value generated from each member.

Retention will be equally important. Alan does not publicly disclose enough information about employer renewals, member churn or contract duration. Strong renewal data would make rapid customer acquisition far more valuable.

A larger valuation becomes credible once Alan combines international growth, recurring employer contracts, group profitability and a rising retained margin. At that point, investors could reasonably see it as a healthcare platform rather than a well-designed insurer.

What Alan must deliver to support a higher valuation

Q18What could cut Alan’s valuation in half?

Alan’s valuation could fall sharply if growth slows before margins improve. A company priced several years ahead has little room for an ordinary performance.

A decline toward 15% annual growth would make the current premium multiple difficult to defend. Public investors already value profitable health insurers growing above 20% at close to one times revenue.

International disappointment would create another problem. Belgium currently carries most of the evidence that Alan can succeed abroad. Weak renewals there, continued small scale in Spain or an expensive Canadian launch would leave investors with a predominantly French insurer.

Large-contract concentration adds volatility. Losing a major government tender could remove tens of thousands of members at once and weaken Alan’s reputation with other public institutions.

Medical inflation could also grow faster than Alan’s pricing. Technology lowers administrative costs, but it cannot stop hospitals, medicines and medical consultations from becoming more expensive.

A final risk comes from the fundraising itself. Part of the latest transaction gave earlier shareholders liquidity. Future investors may become less willing to pay higher prices if existing holders keep selling while group profitability remains unproven.

Alan would not need to collapse operationally for its valuation to fall by half. Slower growth, thin margins and weak international progress would be enough to make €2.5 billion to €3 billion look much closer to public-market reality.

Q19So, is Alan really worth $6.3B today?

On today’s fundamentals, Alan still looks overvalued. The current price becomes reasonable only when we give the company credit for two or three more years of fast growth, wider profitability and successful international expansion.

Alan has already achieved more than a typical insurtech. It serves more than one million people, France is profitable, group losses are falling, and the company is gaining large customers without increasing headcount or sales spending at the same rate.

Its valuation still rests on a flattering interpretation of revenue. Most premium income pays medical claims, recent growth came mainly from adding members, and Alan has not demonstrated strong expansion in revenue per customer.

Public comparisons reinforce that concern. Alignment Healthcare grew almost as quickly while producing positive adjusted EBITDA, yet it trades at a fraction of Alan’s premium multiple. Alan needs to become a substantially better business than Alignment, rather than simply a younger version with a better interface.

We would describe the valuation as aggressive but credible. Alan can grow into it by keeping annual growth near 30%, reaching group profitability around 2027, building a profitable business outside France and increasing the amount of revenue it retains from every member.

Until those conditions are visible, investors are paying for the company Alan may become rather than the company that exists today.